Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $30.11.
A number of brokerages recently issued reports on CABA. Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price on shares of Cabaletta Bio in a report on Friday, June 21st. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price target on shares of Cabaletta Bio in a research note on Monday, June 17th. Wells Fargo & Company cut their price objective on Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a research report on Tuesday, September 17th. Finally, Evercore ISI reduced their price target on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, August 12th.
Read Our Latest Stock Report on CABA
Institutional Investors Weigh In On Cabaletta Bio
Cabaletta Bio Stock Performance
NASDAQ:CABA opened at $4.70 on Friday. The company has a 50-day moving average of $5.62 and a 200-day moving average of $10.42. The firm has a market cap of $226.90 million, a price-to-earnings ratio of -2.75 and a beta of 2.40. Cabaletta Bio has a twelve month low of $3.47 and a twelve month high of $26.35.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). On average, research analysts forecast that Cabaletta Bio will post -2.21 earnings per share for the current year.
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
See Also
- Five stocks we like better than Cabaletta Bio
- What are earnings reports?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 9/16 – 9/20
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.